Curr Opin Investig Drugs 2010,
PMID: 20496258
Bhagwat, Shripad V; Crew, Andrew P
The PI3K/Akt/mTOR pathway is frequently activated in human cancers, and mTOR is a clinically validated target for therapeutic intervention in this pathway. The discovery of the involvement of rapamycin-insensitive mTOR complex 2 (mTORC2) in the activation of Akt, combined with the limited clinical antitumor activity of mTOR complex 1 (mTORC1)-directed rapamycin analogs, have led to the discovery of ATP-competitive selective inhibitors of the mTOR kinase that inhibit the function of both mTORC1 and mTORC2. This review describes progress in the identification of selective and novel inhibitors of mTORC1/2, focusing on the profile of inhibitors that are in clinical development.
Diseases/Pathways annotated by Medline MESH: Neoplasms
Document information provided by NCBI PubMed
Text Mining Data
Akt — mTOR complex 2 (mTORC2): "
The discovery of the
involvement of rapamycin-insensitive
mTOR complex 2 (mTORC2) in the activation of
Akt , combined with the limited clinical antitumor activity of mTOR complex 1 (mTORC1) directed rapamycin analogs, have led to the discovery of ATP-competitive selective inhibitors of the mTOR kinase that inhibit the function of both mTORC1 and mTORC2
"
Manually curated Databases
No curated data.